Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commer...
Ascletis Pharma Inc. announces positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending d...
Bristol Myers Squibb announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline...
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed Enhertu (trastuzumab deruxtecan) in co...
HUTCHMED (China) Limited (“HUTCHMED”) announces that it has completed enrollment of the registration phase of its Phase II trial of savol...
The Leukemia & Lymphoma Society (LLS) announced the first pediatric patient has received treatment in a new subtrial of its Pediatric Ac...
As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off&nb...
Henlius celebrated its World R&D Day 2025, under the theme "Collaborate to Create", bringing together senior executives, experts and indust...
Akeso, Inc. is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from ...
SparX Biopharmaceutical Corp. announced that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific ant...
CSL Behring K.K. President and Representative Director: Izumi Yoshida) announced that it launched ANDEMBRY® Subcutaneous Injection 200 mg P...
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding ...
As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of Buffalo (SUNY) spin-off&nb...
Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced the dose administration for the first patient in a Phas...
© 2025 Biopharma Boardroom. All Rights Reserved.
